<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04257734</url>
  </required_header>
  <id_info>
    <org_study_id>CONSG1</org_study_id>
    <nct_id>NCT04257734</nct_id>
  </id_info>
  <brief_title>Epidemiologic and Clinical Characteristics of Optic Neuritis in China</brief_title>
  <official_title>Epidemiologic and Clinical Characteristics of Optic Neuritis in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University Health Science Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a hospital-based retrospective multi-center study on epidemiologic and clinical
      characteristics of optic neuritis among Chinese. The investigation will cover about 29
      provinces or municipalities all around China.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This national investigation will be conducted to describe the epidemiology and clinical
      characteristics of optic neuritis in China. All the patients will be divided into 3 groups
      according to the serum demyelinating antibodies (Aquaporin-4 antibody seropositive group,
      Myelin oligodendrocyte glycoprotein antibody seropositive group and double seronegative
      group). The investigator will analyze the differences among the three groups.

      Primary outcomes:

        -  To dig out the different visual acuity (VA, LogMAR) prognosis among the three groups;

             -  To calculate the annual relapse rate (ARR) differences among the three groups
                (relapse times in all the follow-up time in each group/ follow-up time (years) in
                all in each group).

      Secondary outcomes:

        -  Other epidemiological and clinical characteristics of optic neuritis patients will be
           analyzed among the three groups;

             -  Orbital or Brain MRI is required in this study, which could avoid the misdiagnosis.
                We will collect and analyze these MRI data too (including the optic nerve lesions
                in T2 weight images and T1 enhanced MRI);

                  -  Results of optical coherence tomography (OCT) (including peripapillary retinal
                     nerve fiber layer, macular thickness ,and ganglion cell and inner plexiform
                     layer complex) at different time point are also needed in this study. However,
                     OCT is not necessarily required;

                       -  Visual fields at different time points are also encouraged to provide if
                          they are available.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>At least 1 year from the attack to the final visit</time_frame>
    <description>Last visual acuity records in the hospital</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annual Relapse Rate</measure>
    <time_frame>At least 1 year from the attack to the final visit</time_frame>
    <description>Calculated annual relapse rate of different subgroups in the cohort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epidemiologic characteristics of optic neuritis</measure>
    <time_frame>At least 1 year from the attack to the final visit</time_frame>
    <description>Gender, age of first attack, location</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical characteristics of optic neuritis</measure>
    <time_frame>At least 1 year from the attack to the final visit</time_frame>
    <description>Visual acuity at nadir, pain, optic disc edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical Coherence Tomography</measure>
    <time_frame>At least 1 year from the attack to the final visit</time_frame>
    <description>RNFL, macular thickness and GCIPL at different time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Orbit or Brain MRI at the attack</measure>
    <time_frame>At least 1 year from the attack to the final visit</time_frame>
    <description>Lesions of the optic nerve</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Optic Neuritis</condition>
  <arm_group>
    <arm_group_label>optic neuritis</arm_group_label>
    <description>Aquaporin 4 antibody seropositive optic neuritis patients, Myelin oligodendrocyte glycoprotein antibody seropositive optic neuritis patients, and double antibodies seronegative optic neuritis patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>observation</intervention_name>
    <description>different serum antibodies status</description>
    <arm_group_label>optic neuritis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Optic neuritis patients with complete medical records in multicenter from China.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis of optic neuritis

          2. The patients' medical records were complete

        Exclusion Criteria:

          1. Patients with unclear diagnosis of optic neuritis

          2. Incomplete medical records
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shihui Wei, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Ophthalmology, the Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mo Yang, Ph.D</last_name>
    <phone>+86-010-66938375</phone>
    <email>doctoryangmo@icloud.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mengying Lai, M.D</last_name>
    <phone>+86-010-66938175</phone>
    <email>78313749@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100835</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mo Yang, PhD</last_name>
      <phone>+86-183-1009-8349</phone>
      <email>doctoryangmo@icloud.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>July 18, 2020</last_update_submitted>
  <last_update_submitted_qc>July 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Wei Shihui</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>optic neuritis</keyword>
  <keyword>clinical Characteristics</keyword>
  <keyword>epidemiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Optic Neuritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>It is a multi center study of optic neuritis, the individual participant data belongs to every single center. Now, we are applying for the approval. However, the details will not be available until all the centers approved.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

